MIAMI, FL, April 19, 2026. FormBlends, a telehealth platform focused on medically supervised GLP-1 therapy and peptide research, today released its 2026 State of Peptides and GLP-1 Regulation report. The report maps how the Robert F. Kennedy Jr. Department of Health and Human Services, the FDA Center for Drug Evaluation and Research, and a pipeline of new obesity drugs from Eli Lilly, Novo Nordisk, Boehringer Ingelheim, and Roche are reshaping what Americans can legally access for weight management, metabolic health, and peptide therapy through the end of the decade.
The full report is available at formblends.com/report/state-of-peptides-and-glp1-regulation-2026 and anchors the company's research hub, which brings together FDA guidance documents, bulk substances list updates, ClinicalTrials.gov pipeline data, and plain-English explainers of every compound currently used in the GLP-1 and peptide space.
"We built this because nobody else was tracking all of it in one place," said a FormBlends spokesperson. "Patients, compounding pharmacies, even clinicians are asking the same questions every week: what's legal right now, what's under review, what's coming. The answer keeps changing. We decided to just keep up with it and publish the work."
A New Era Under RFK Jr. and the Make America Healthy Again HHS
Robert F. Kennedy Jr. was confirmed as HHS Secretary in February 2025. It was the biggest reset of federal health priorities in twenty years. The administration's Make America Healthy Again agenda put metabolic disease, ultra-processed food, and chronic illness at the center of the federal health conversation in a way the prior administration didn't.
What's changed for the peptide and GLP-1 world since then is harder to summarize than the political headlines suggest.
The tone has shifted. Kennedy has talked openly about using peptides himself, which on paper changes nothing, but in practice has changed what members of Congress, state medical boards, and health trade press are willing to say out loud. Peptides get discussed the way testosterone started getting discussed around 2015. That's not a regulatory change. It's a precondition for one.
On the compounding side, the agency's 2023 to 2025 moves to end the GLP-1 shortage and tighten 503A rules drew a lot of public comments. Patient groups, compounding trade associations, and several state AGs asked FDA through 2025 to revisit how fast it unwound the shortage for semaglutide and tirzepatide, and to explain what happens to patients who can't pay branded-drug list price. The new HHS has asked FDA to publish more data on how it calls shortages and to address access concerns. That's slow, not dramatic, but it's a different posture than the one before.
The bigger story is the peptide bulk substances review. A lot of compounds that had been compounded for years (BPC-157, Thymosin Beta-4, CJC-1295, Ipamorelin, Sermorelin, and others) got moved to Category 2 on the FDA 503A list in September 2023, which ended most legal bulk compounding overnight. Industry groups and clinicians have been asking HHS to reconsider ever since. The 2026 budget request actually includes new language about "evidence review for therapeutic peptides," which suggests at least some of those Category 2 designations will be looked at again before 2027. We don't know which ones yet.
The report's opening section walks through each of these themes, cites the specific Federal Register notices that triggered the current rules, and explains what patients can and cannot expect in the near term. Readers can find the full regulatory summary at formblends.com/science.
The FDA Bulk Substances List and Why It Matters
Most conversations about the legality of peptides in the United States come back to one document: the FDA 503A Bulk Drug Substances list. That list is the clearest signal of which raw peptide powders a 503A compounding pharmacy can legally use for patient-specific prescriptions.
The list has three practical categories. Category 1 contains substances that FDA is willing to allow under the usual compounding rules while further review is done. Category 2 contains substances FDA has identified as having significant safety risks. Category 3 contains substances that have been reviewed and do not meet the criteria for inclusion.
In September 2023, FDA moved a set of peptides into Category 2. That single action ended most legal compounding of BPC-157, Thymosin Beta-4, CJC-1295 without DAC, Ipamorelin, KPV, Selank, Semax, and several others from 503A pharmacies. A parallel action through the 503B outsourcing facility rules limited the pathway for larger-scale compounding.
What changed in 2025 and 2026 is not the list itself but the posture toward it. FDA has opened a new public docket for therapeutic peptide review. The docket invites clinical evidence, pharmacovigilance data, and formal nominations for peptides to be reconsidered. HHS has signaled that the agency should move faster and that the existing list does not reflect current evidence for several compounds.
Peptides most commonly named in public comments and industry petitions as candidates for return to legal compounding include:
- BPC-157 (Body Protection Compound 157), a pentadecapeptide derived from a gastric protein. Used for tendon, ligament, and gut healing research. Blocked from 503A compounding since late 2023.
- TB-500 and Thymosin Beta-4, studied for tissue repair and cardiac recovery.
- CJC-1295 and Ipamorelin, growth hormone secretagogue peptides used historically for adult growth hormone support and recovery.
- Sermorelin, a growth hormone releasing hormone analog with decades of human data.
- KPV, a tripeptide fragment of alpha-MSH studied for gut inflammation.
- Selank and Semax, Russian-developed peptides with research in anxiety, cognition, and neuroprotection.
- Epithalon, studied for telomere biology.
- MOTS-c, a mitochondrial-derived peptide studied for metabolic function.
None of these are FDA-approved drugs. None are currently legal to compound from bulk for patient use in the United States. The report is careful to separate what is legal today, what is under review, and what would require an entirely new approval pathway.
The 2026 State of Peptides report explains the specific regulatory mechanics that would allow any of these to return to legal compounding, what clinical evidence FDA has said it wants to see, and which industry groups are funding the studies to produce that evidence. A searchable table of every peptide and its current legal status is maintained at formblends.com/peptides.
The Two Paths Back to Legal Compounding
There are two realistic paths for any of the listed peptides to return to lawful patient use in the United States. The first is reclassification on the 503A bulk substances list from Category 2 back to Category 1 or a new formal Category 1A. That requires the agency to be satisfied that the safety concerns that drove the 2023 reclassification have been addressed, either through new clinical data, new pharmacovigilance data, or new synthesis and purity standards. Industry groups including the Alliance for Pharmacy Compounding have been working on each of these inputs since the reclassification was announced.
The second path is formal FDA approval of a specific peptide as a drug. This is the pathway Semaglutide followed. It is slow, expensive, and requires a sponsor willing to carry the peptide through phase 1, phase 2, and phase 3 trials. It does not apply to every compound on the list. Many of these peptides are off-patent or have never had a single commercial sponsor. Without a sponsor, the approval pathway does not exist, and reclassification on the bulk list is the only realistic option.
The report walks through each peptide and assesses which path is most likely, who the potential sponsors or petitioners are, and what the realistic timeline looks like based on current FDA docket activity. None of this is a prediction. It is a map of the process and the actors.
What RFK Jr. Has Actually Said About Peptides
Kennedy's public comments on peptide therapy started showing up in long-form interviews around 2023 and 2024, and they didn't stop after confirmation. He's talked about using peptides for joint recovery. He's named specific compounds. None of that is law. It is however the kind of thing that moves slowly into agency posture.
A few things have actually changed on paper since.
The HHS Office of the Secretary has asked FDA to put out a public-facing explainer on how peptides are regulated. That document is drafted and is expected to clear review in the back half of 2026. It'll be the first time the agency has published a consumer-level guide that separates an FDA-approved peptide drug, a compounded peptide prescription, and a research-only peptide product sold online.
NIH has also been asked to steer more grant funding toward peptide research in metabolic disease, wound healing, and neurodegeneration. The NIH RePORTER database shows the activity ticking up in the 2025 and 2026 fiscal years, though you don't really see the effect of a grant cycle until two years later.
The FTC has quietly paused a handful of peptide-marketing enforcement actions that had been opened under the prior administration. That isn't a green light. The agency has said false medical claims and unapproved drug marketing are still under its jurisdiction. It does say something about federal posture while the rules are being rewritten.
The report includes a timeline of every public statement from Secretary Kennedy on peptide therapy since 2022, every Federal Register notice from FDA on the topic since 2023, and every relevant budget document from HHS in the 2026 fiscal year. That timeline is updated monthly at formblends.com/research.
The Obesity Pipeline Through 2028: 30+ Compounds in Active Development
While peptide regulation is getting rewritten, the obesity drug class is running its own transformation in parallel. Most patients only know two compounds: semaglutide and tirzepatide. Both came off the FDA shortage list in 2024 and 2025, and that ended large-scale legal compounding for both.
What's coming behind them isn't just a longer list of GLP-1 agonists. It's more receptors per molecule, more oral options, and a whole tier of non-incretin mechanisms that target muscle, mitochondria, the cannabinoid system, and the gut fat-absorption pathway. We've tracked more than thirty compounds in trials or advanced preclinical, sorted below by mechanism complexity.
The full pipeline map lives at formblends.com/pipeline. What follows is every compound we think is worth watching through 2028.
Tier 1: Quintuple Agonists, the New Ceiling
Lilly Quintuple Agonist (preclinical). Eli Lilly, with the Indiana Biosciences Research Institute, has a single molecule that hits five receptors at once: GLP-1, GIP, glucagon, amylin, and calcitonin. The rat data is on the schedule for ADA 2026 on June 7, Poster 2839-LB, Jonathan Douros, PhD as lead investigator. The compound reportedly beat retatrutide for weight loss in obese rats. Rats aren't humans. If it translates, this is a generational jump.
Tier 2: Quadruple Agonists
NA-931 / Bioglutide (Biomed Industries, Lloyd Tran, PhD). An oral small molecule covering GLP-1, GIP, glucagon, and IGF-1. A 13-week phase 2 in 125 adults reportedly produced up to 13.8 percent weight loss with no muscle loss, and 72 percent of participants hit 12 percent or more versus 2 percent on placebo (NCT06563753). The IGF-1 arm is the muscle-preservation bet. Problem: outside analysts have publicly challenged the credibility of the data, and none of it's been peer reviewed. We're including it because the signal, if real, is big. We aren't treating it as settled.
Tier 3: Triple Agonists
Retatrutide (LY3437943, Eli Lilly). GLP-1 / GIP / glucagon triple agonist. The TRIUMPH and TRANSCEND phase 3 programs together enrolled over 5,800 patients. TRIUMPH-4 hit 28.7 percent weight loss at 68 weeks on the 12 mg dose, an average of 71.2 pounds off. TRANSCEND-T2D-1 hit 16.8 percent weight loss plus a 2.0 percentage point A1C drop in T2D. Seven more phase 3 readouts are due through 2026. FDA filing is expected late 2026, with a decision window opening 2027 to 2028. One thing to watch: 20.9 percent of patients at 12 mg reported dysesthesia (abnormal skin sensation). Whether that holds in the larger data set matters for the commercial story.
Survodutide (BI 456906, Boehringer Ingelheim and Zealand Pharma). A dual GLP-1 and glucagon agonist, not a true triple. Phase 2 data reported approximately 19 percent weight loss at 46 weeks without a plateau, and improvement in MASH without fibrosis worsening at 48 weeks. The SYNCHRONIZE phase 3 program in obesity and the LIVERAGE phase 3 program in MASH are both active. Key ClinicalTrials.gov identifiers include NCT06077864 (SYNCHRONIZE cardiovascular outcomes component) and NCT06309992 (MASH-focused phase 3). Survodutide is investigational in the United States, is not FDA approved as of April 2026, and is not legally available through United States compounding pharmacies outside approved clinical trial pathways.
Mazdutide (IBI362 / LY3305677, Innovent Biologics, licensed from Lilly). A GLP-1 and glucagon dual agonist. Approved in China in 2025. The DREAMS phase 3 program in China reported 14.0 percent weight loss versus 0.3 percent weight gain on placebo at 48 weeks. A 9 mg dose in obesity plus NAFLD reported 13.3 percent loss with 31.7 percent of participants achieving 15 percent or greater loss. DREAMS-3, the first head-to-head trial of mazdutide against semaglutide, is expected to complete in the first half of 2026.
BI 3034701 (Boehringer Ingelheim and Gubra). Boehringer's second-generation triple agonist, positioned as a potential successor to survodutide. Phase 1 first-in-human trial is ongoing (NCT06352437). Limited public data.
Novo Nordisk Triple Agonist (licensed from United Biotechnology). Novo's direct answer to retatrutide. Licensed from United Biotechnology in 2025 for a reported 200 million dollar upfront. Chinese-origin molecule. Post-Phase 1b and advancing. Limited public data.
Kailera Triple Agonist (Kailera Therapeutics). A well-funded preclinical GLP-1, GIP, and glucagon triple agonist. Kailera has raised approximately 600 million dollars to develop the asset for obesity and type 2 diabetes. Preclinical stage as of April 2026.
Tier 4: Dual Agonists
Amycretin / Zenagamtide (Novo Nordisk). A unimolecular GLP-1 and amylin dual agonist in both subcutaneous and oral formulations. Phase 3 programs for both formulations started in the first quarter of 2026. Novo materials increasingly refer to the phase 3 asset under the zenagamtide name. Phase 1b/2 reported approximately 22 percent weight loss. Phase 2 in diabetes reported 7.6 percent placebo-adjusted weight loss on the oral form with no plateau. A single-molecule dual mechanism is structurally different from the co-formulation approach of CagriSema, and Novo considers amycretin its flagship next-generation obesity asset.
MariTide (maridebart cafraglutide / AMG 133, Amgen). An antibody-peptide conjugate that is a GLP-1 agonist and a GIP antagonist. Phase 3. Phase 2 reported up to 20 percent weight loss at one year. Phase 1 reported 14.5 percent weight loss. Monthly subcutaneous dosing is a potential market differentiator. The GIP antagonism mechanism is the inverse of tirzepatide's GIP agonism, and the fact that both approaches produce weight loss has drawn attention from researchers studying incomplete understanding of GIP biology.
VK2735 (Viking Therapeutics). A dual GLP-1 and GIP agonist. The VANQUISH phase 3 program is active for the subcutaneous form. The oral program (VENTURE) is earlier stage. Subcutaneous phase 2 reported 14.7 percent weight loss at 13 weeks, 13.1 percent placebo-adjusted. Oral VENTURE reported 12.2 percent weight loss at 13 weeks. Effective down-titration maintenance from 90 mg to 30 mg was observed. VK2735 has been a persistent merger and acquisition target.
CagriSema (Novo Nordisk). A co-formulated combination of semaglutide (GLP-1) and cagrilintide (amylin and calcitonin). NDA filed in December 2025. FDA decision expected in the second half of 2026. Commercial launch expected in 2027. REDEFINE-1 reported 22.7 percent weight loss at 68 weeks. REDEFINE-2 in type 2 diabetes reported 13.7 percent loss. Caveat: the trial missed Novo's internal 25 percent efficacy target, which moved the stock sharply at the time of the readout. CagriSema is currently the closest to market of any multi-mechanism obesity drug.
Pemvidutide (ALT-801, Altimmune). A unimolecular GLP-1 and glucagon dual agonist. Subcutaneous. Phase 2 wrapping up with MASH trials in parallel. End-of-Phase-2 alignment meeting with FDA was announced in November 2024. Phase 1 reported up to 10.3 percent weight loss at 12 weeks. The differentiation angle is body composition, lipid profile, and liver fat rather than pure weight-loss percentage, which may matter most if pemvidutide cannot match retatrutide on headline efficacy.
CT-388 (Roche, via Carmot Therapeutics). A dual GLP-1 and GIP agonist. Phase 2. Roche's primary obesity asset following the Carmot Therapeutics acquisition.
AZD9550 + AZD6234 (AstraZeneca ASCEND program). A two-molecule combination, with AZD9550 as a GLP-1 and glucagon dual agonist and AZD6234 as a selective amylin agonist. Phase 2b combination trial (ASCEND) is active, and the individual assets are in phase 2. AstraZeneca positions this as a "triple mechanism" strategy across two molecules, aimed at fat-selective weight loss and organ protection. Part of a 1.2 billion dollar CSPC Pharmaceutical deal in February 2026 that expanded AstraZeneca's obesity pipeline.
Ecnoglutide (XW003, Sciwind Biosciences). A biased GLP-1 agonist that favors cAMP signaling over beta-arrestin recruitment. Phase 3 (SLIMMER trial). Phase 3 reported 13.2 percent weight loss at 32 weeks at the 2.4 mg dose. Phase 2 reported up to 14.7 percent total body weight loss at 26 weeks. Biased signaling may amplify appetite suppression relative to standard GLP-1 agonists. Chinese-developed.
Tier 5: Next-Generation Single Agonists
Orforglipron (Eli Lilly, licensed from Chugai 2018). A once-daily oral small molecule GLP-1 agonist, not a peptide. FDA PDUFA date April 10, 2026, with approval considered imminent at the time of this release. Phase 3 reported 12.4 percent weight loss. A February 2026 Lancet publication reported superior A1C and weight outcomes compared with oral semaglutide in a head-to-head type 2 diabetes trial. The market-changing feature is no food or water restriction at dosing, which removes the adherence friction that has limited oral semaglutide uptake. Lilly has indicated launch pricing in the 149 to 399 dollars per month range through LillyDirect, which if accurate would reset the price floor for GLP-1 therapy globally.
PF-3944 / MET-097i (Pfizer, via Metsera acquisition November 2025). An ultra-long-acting, fully biased injectable GLP-1 agonist. Phase 3 (VESPER-4 registrational). VESPER-3 hit its primary endpoint at 28 weeks. Weight loss continued after a weekly-to-monthly dosing switch with no plateau. Monthly maintenance dosing is the commercial angle. Pfizer has indicated more than twenty obesity trials planned across 2026.
Aleniglipron (Structure Therapeutics). An oral small molecule GLP-1. Phase 2 complete. End-of-Phase-2 FDA meeting in the first quarter of 2026. Phase 3 expected mid-2026.
Danuglipron (Pfizer). An oral GLP-1. Phase 2b. Reported up to 13 percent placebo-adjusted weight loss at 32 weeks across dose groups.
Elecoglipron (AZD5004 / ECC5004, AstraZeneca and Eccogene). An oral small molecule GLP-1. Licensed from Shanghai biotech Eccogene in November 2023. Phase 1b topline from China reported in February 2026 showed 5.8 percent weight loss over 4 weeks with acceptable tolerability. Moving to phase 2.
GZR18 (Gan & Lee Pharmaceuticals, China). A bi-weekly injectable GLP-1. Phase 2b complete (CTR20231695). Reported 17.29 percent weight loss at 48 mg bi-weekly over 30 weeks, and 17.78 percent at 24 mg once weekly. The bi-weekly dosing cadence is the differentiation angle.
TG103 (CSPC Pharmaceutical Group, China). A GLP-1 Fc-fusion protein. Phase 3 (NCT05997576). Phase 1b reported 5.35 to 5.65 kg weight loss at 12 weeks across 15 to 30 mg doses. Extended half-life is the engineering story.
Tier 6: Amylin Pathway, the Muscle-Sparing Bets
Petrelintide (Roche and Zealand Pharma). A clean amylin analog monotherapy. Phase 2. The amylin pathway is attracting heavy investment as a muscle-sparing approach to weight loss, either as a standalone therapy for GLP-1-intolerant patients or as a combination partner.
Cagrilintide monotherapy (Novo Nordisk). An amylin and calcitonin dual agonist. Phase 2 as monotherapy and a component of CagriSema. 10.8 percent mean weight loss at 4.5 mg over 26 weeks as monotherapy.
AZD6234 (AstraZeneca). A selective amylin receptor agonist. Phase 2b (APRICUS), completing in 2026. Positioned for patients who cannot tolerate GLP-1s. Preclinical data suggested fat-selective loss with lean mass preservation.
NNC0174-0833 (Novo Nordisk). An amylin receptor agonist. Phase 1.
Tier 7: Non-Incretin Mechanisms, the Backup and Combination Bets
The most important story in the 2028 pipeline is not another GLP-1. It is the emergence of entirely non-incretin mechanisms that can either replace GLP-1 therapy for intolerant patients or combine with it to produce better body composition, better liver outcomes, or better metabolic profiles.
Bimagrumab (Eli Lilly, via Versanis Bio acquisition). A monoclonal antibody against activin type II receptors. Phase 2b BELIEVE complete, phase 3 planning. The BELIEVE combination arm reported 20.2 percent weight loss with bimagrumab plus high-dose semaglutide at 48 weeks, sustained at 22 percent at 72 weeks. The combination preserved lean mass while reducing visceral fat. Bimagrumab monotherapy reported 9.7 to 19.8 percent loss, almost entirely from fat mass. This is the most advanced answer to the GLP-1 muscle-loss concern.
Taldefgrobep Alfa (Biohaven, BHVN). A myostatin-activin pathway inhibitor. Adnectin format with greater ligand specificity than bimagrumab. Phase 2 obesity (enrollment complete March 2026, topline expected in the second half of 2026). Prior spinal muscular atrophy studies reported more than 6 percent fat mass reduction and up to 4 percent lean mass gain, with a 168-week SMA data set showing 5.6 percent lean body mass increase versus 2.0 percent on placebo. The obesity phase 2 is a rescue pivot after the SMA program missed its primary endpoint. Once-weekly or once-monthly dosing is possible.
Monlunabant (INV-202, Novo Nordisk, via Inversago acquisition for 1.1 billion dollars). A second-generation, peripherally restricted CB1 inverse agonist. Phase 2a complete. Phase 2b/3 registrational program planned for mid-2026. Phase 2a reported 7.1 kg weight loss at 10 mg versus 0.7 kg on placebo at 16 weeks. Higher doses did not produce meaningfully more loss and produced dose-dependent adverse events with elevated withdrawal rates. Historical context: first-generation CB1 inverse agonist rimonabant was withdrawn for psychiatric side effects. Monlunabant is engineered to minimize brain penetration.
Nimacimab (Skye Bioscience, SKYE). A peripherally restricted monoclonal antibody against the CB1 receptor. Phase 2a CBeyond complete. 26-week extension data in early 2026. The nimacimab plus semaglutide combination reported significantly boosted weight loss versus semaglutide alone. Monotherapy at 1.5 percent loss did not beat placebo statistically. The combination signal and clean safety are the story. The antibody format cannot cross the blood-brain barrier, avoiding rimonabant-style psychiatric concerns.
HU6 (Rivus Pharmaceuticals). A controlled metabolic accelerator. A mitochondrial uncoupler. Phase 2 (HuMain-HFpEF) and Phase 1 in childhood obesity. Phase 2a in obesity-related HFpEF reported significant weight loss versus placebo at 3 months with fat mass reduction and no lean mass loss. Entirely novel mechanism. Preserves muscle by design because the metabolic increase happens in fat tissue rather than through appetite suppression.
S-309309 (Shionogi). An oral MGAT2 inhibitor. Phase 2 with 365 participants in a 24-week program. Blocks an intestinal fat absorption pathway. Non-hormonal. Also relevant for MAFLD and MASH.
Vutiglabridin (HSG4112, Glaceum). A PON1 modulator derived from the licorice compound glabridin. Oral. Phase 2 ongoing (NCT05197556). Natural-product-derived small molecule with an anti-oxidative and anti-inflammatory mechanism.
DA-1726 (NeuroBo Pharmaceuticals). An oxyntomodulin analog with GLP-1 and glucagon activity. Phase 1 MAD part 3 interim mid-2026, topline in the second half of 2026. Preclinical reported superior weight loss versus semaglutide and survodutide in mouse models with lean mass preservation.
BI 1820237 (Boehringer Ingelheim and Gubra). A long-acting NPY-Y2 receptor agonist. Phase 1. Phase 1 combination with liraglutide reported safety, decreased energy intake, and delayed gastric emptying. Preclinical combination with semaglutide reported 20.5 percent weight loss. An entirely different gut hormone axis (peptide YY pathway) from the incretin family.
APHD-012 (Aphaia Pharma, Switzerland). Distal jejunal-release dextrose beads designed to mimic the gut-hormone effects of bariatric bypass surgery. Phase 2. A wild card mechanism that is not a drug in the conventional sense and does not involve a hormone analog at all.
Setmelanotide (Rhythm Pharmaceuticals). An MC4R agonist. FDA-approved in 2020 for rare genetic obesity syndromes (BBS, POMC, PCSK1, LEPR, and hypothalamic obesity). Expanded pediatric approval (ages 2 to 6) granted through the EMA. Daily subcutaneous injection. Side effects include depression, suicidal ideation, and hyperpigmentation. Not a general-population therapy. Included in the report as the reference standard for the genetic obesity category.
What the Full Map Tells Us
A few things are happening at once here, and it's easy to mix them up.
The receptor count keeps going up. Three was the ceiling when retatrutide entered phase 3. Lilly's quintuple agonist, if the rat data translates, moves that to five. Whether the human body tolerates activation of five receptors at once is a separate question nobody has answered yet.
The muscle-preservation problem is getting serious attention from three different directions. You can build a better incretin that includes IGF-1 signaling (NA-931, assuming the data is real). You can add an amylin partner (petrelintide, CagriSema, AZD6234, NNC0174-0833). Or you can block myostatin and activin directly with an antibody or adnectin (bimagrumab, taldefgrobep). One or more of these wins, and combination regimens become the default within a few years.
Oral and long-acting formats are the other race. Orforglipron hits the market in April 2026 if the PDUFA holds. Oral amycretin, oral VK2735, elecoglipron, monthly PF-3944, and bi-weekly GZR18 are all behind it. The weekly subcutaneous injection isn't going away, but it's not the only format anymore.
Outside the incretin family entirely, HU6's mitochondrial uncoupler, the CB1 inverse agonists, MGAT2 inhibitors, NPY-Y2 agonists, and MC4R agonists are all in trials. These matter as backup mechanisms for GLP-1 non-responders and as combination partners. None of them is going to replace GLP-1 therapy. Any of them could add 3 to 7 percentage points of weight loss on top of one.
And China. Mazdutide is already approved there. Ecnoglutide, GZR18, TG103, NA-931, elecoglipron are all Chinese assets in late-stage trials. AstraZeneca's 1.2 billion dollar CSPC Pharmaceutical deal in February 2026 wasn't a one-off. More Western licensing deals are coming.
Every one of these compounds has its own page in the report, at formblends.com/pipeline. Each page links out to the published trial, the ClinicalTrials.gov entry, the company's investor materials, and outside analyst commentary on likely launch timing.
Why the Pipeline Changes the Compounding Conversation
For two years the debate about compounded GLP-1s has been stuck on one question: when FDA ends the shortage, can pharmacies keep compounding?
That question is about to get outdated. The next generation of obesity drugs isn't structurally like semaglutide. Retatrutide, survodutide, amycretin, and CagriSema are all harder to synthesize. Orforglipron isn't even a peptide, which puts it in a completely different manufacturing and regulatory bucket. Petrelintide and cagrilintide are peptides but the scale and stability profiles don't match semaglutide either.
So the compounding industry is going to face a different set of questions with the 2027 pipeline than it did with the 2023 shortage. Some of these compounds may never be compoundable at scale. Some might be, under specific clinical conditions. It's going to come down to the synthesis route, whether FDA calls a shortage, and what the compounding industry's posture looks like under the new HHS.
The report works through each compound and the likely legal path to access. It also walks through the economics, which tend to get ignored in the compounding debate. A five-dollar daily orforglipron pill with 12 percent weight loss is a different commercial product than a three-hundred-dollar weekly injection with 20 percent weight loss. If orforglipron prices aggressively through LillyDirect, it'll do more to globalize GLP-1 access than any regulatory action of the last five years.
International Context
The United States isn't the only country rewriting these rules in 2026. EMA, the UK's MHRA, Health Canada, and Australia's TGA have each put out updated guidance on GLP-1 access, compounding, and peptide therapy in the last twelve months.
Australia's TGA tightened compounded semaglutide rules in late 2024 and has stayed stricter than the US since. The UK has done the middle path, with NICE recommending tirzepatide for obesity but rolling out access more slowly than patient groups wanted. Canada's focused mostly on supply chain and pricing, with Health Canada playing a more active role in prescribing guidance than most expected. The EU is still working out how to reconcile different national compounding regimes against emerging EMA guidance on incretins.
On peptides specifically, the picture's split. Some jurisdictions that were more permissive than the US in 2022 are tighter now. Others are going the other way. Mexico is a major peptide-tourism destination for American patients, but quality control and clinical oversight there varies clinic to clinic. Caveat emptor applies.
The report includes a country-by-country summary. As far as we know, it's the first public resource to map peptide and GLP-1 rules across all these jurisdictions in one place.
State-Level Activity
Federal regulation is one layer. Every state also has its own Board of Pharmacy, its own medical board, and its own telemedicine rules. The report carries a 50-state survey of pending legislation and regulatory action on peptide therapy, compounded GLP-1 access, and telemedicine oversight.
A few state-level items worth flagging. Texas has moved to clean up physician supervision standards for compounded GLP-1 prescribing. Florida has introduced legislation on telehealth-issued controlled substances that, while not aimed at peptides directly, changes how telehealth platforms operate. Louisiana and Tennessee are both looking at in-state compounding licensing requirements. California's legislative calendar has proposals that would tighten or widen access depending on which bill you're reading. Colorado has a working group on peptide therapy practice guidelines.
No single state action changes the national picture. The collective effect is different. Peptide and GLP-1 practice is getting rewritten at every layer of American medicine in 2026, not just the federal one. Any clinician practicing across state lines via telemedicine has to track all of it. We maintain an internal state-level matrix and refresh it quarterly.
One Honest Note on Safety
Peptide therapy and GLP-1 therapy are real medical interventions and they get treated too casually in parts of the online conversation. There's a real difference between a peptide studied in a clinical trial, a peptide compounded under a valid prescription from a 503A pharmacy, and a peptide sold as a research chemical on a website with no license. Those aren't three versions of the same thing. They're three different categories with totally different safety, legal, and quality profiles.
Anyone pursuing peptide or GLP-1 therapy should do it with a licensed clinician, with lab monitoring, and for a real medical reason. The serious adverse events we've seen over the past five years in unregulated use tend to be the boring ones. Contamination. Impurities. Dose errors. A delayed diagnosis of something else entirely because the patient was self-medicating and didn't go to a doctor. None of this is new and almost all of it is preventable with oversight and a regulated supply chain.
FormBlends only sells products that fit United States law today, and we'll keep publishing on the full category for educational purposes, with clear markers for what is and isn't legal.
The State of Peptide Research in 2026
The regulatory story is half the picture. The other half is the actual science, which has moved fast in the last five years for reasons that don't have much to do with weight loss at all.
Classes under active academic and industry study right now:
- Senolytic peptides that target senescent cells. FOXO4-DRI has generated attention since its 2017 publication in Cell, and newer analogs are in preclinical development.
- Mitochondrial-derived peptides including MOTS-c, humanin, and SHLP family peptides. Research is moving from animal models into early human studies in metabolic disease.
- Anti-fibrotic peptides for lung, kidney, and liver disease. Several candidates are in phase 1 or phase 2 trials sponsored by academic centers.
- Cardiac regeneration peptides including hydrogel-delivered peptide analogs for post-infarction repair.
- Immunomodulatory peptides including the thymosin family and newer antimicrobial peptides being studied for resistant infections.
- GLP-1 conjugates including peptide-drug conjugates that deliver payload molecules specifically to GLP-1 receptor-expressing tissues.
None of these are consumer products. All of them are real science with peer-reviewed publications and actual trials behind them. The report carries an annotated bibliography of the most-cited peptide papers from 2024 through early 2026 and a glossary of every term a patient or clinician might run into in the trade press.
Plain-English summaries of each research area live at formblends.com/research.
Real-World Evidence on GLP-1s
The other big research story of 2026 is long-term real-world data on the GLP-1 class. Semaglutide and tirzepatide have been in wide clinical use for years now. Big data sets from health systems in the US, the UK, and Scandinavia are coming out at a pace that just wasn't possible two years ago. Papers have looked at cardiovascular outcomes, renal outcomes, cognition, substance use, depression, and cancer risk signals.
The picture is better than a lot of the early skeptics predicted. It's also more complicated than the hype. Different GLP-1 compounds appear to have different off-target benefits and different side effect profiles, and the field is only starting to sort out why. The report summarizes the most-cited real-world publications from 2024 and 2025 and spells out what each one actually establishes and what it doesn't.
Someone starting GLP-1 therapy in 2026 isn't making the same decision a patient in 2023 was making. The drugs are better understood. The side-effect management has gotten more sophisticated. The clinical conversation has shifted from "this is a weight loss product" toward "this is a metabolic therapy that happens to produce weight loss."
What FormBlends Offers and What It Doesn't
FormBlends is a telehealth platform. The commercial side is narrow on purpose. We offer two compounded GLP-1 products with a full medical assessment and clinician oversight: compounded semaglutide and compounded tirzepatide. That's it. No patient gets a prescription without a real evaluation from a licensed clinician, and not every patient is a candidate.
We don't sell BPC-157. We don't sell TB-500, CJC-1295, Ipamorelin, Sermorelin, MOTS-c, Epithalon, KPV, Selank, or Semax. We don't sell any peptide on the FDA Category 2 bulk substances list. We don't sell research chemicals. We don't sell anything from an overseas supplier that's not operating under United States law.
What we do publish, freely, is information. The research library is the biggest part of what FormBlends actually is. Every compound page carries:
- Current FDA status
- Current DEA status where it applies
- Pharmacology summary with named studies
- Currently enrolling trials pulled from ClinicalTrials.gov
- Known safety signals
- Jurisdictional notes for the United States, Canada, the United Kingdom, the European Union, and Australia
- A date stamp on every field
Editorial rule: no claim goes on the site unless it can be traced to a named source. No compound is called safe or effective without a specific trial behind that claim. No product is listed as available unless we actually carry it.
"Patients know more than the industry gives them credit for," the FormBlends spokesperson said. "If you tell them what's legal, what's still investigational, and what the actual trial data says, they can have a real conversation with their own clinician. We're not trying to be the doctor. We're the reference."
Patients who want to begin a medical assessment can start at rx.formscripts.com/quiz/general/short. Clinicians, journalists, researchers, and industry observers who want access to the research hub can explore the library at formblends.com/peptides and formblends.com/pipeline.
How the Research Library Actually Gets Built
The editorial side is slower than the marketing playbook would suggest. Every page on the research library has a named editorial writer, goes through a licensed clinician review, and carries a visible date stamp. Every factual claim points to the source it came from. Every product page pulls apart what's legal from what's still investigational. We don't run synthetic reviews, fabricated testimonials, or placeholder ratings.
The full editorial policy is published on the site. If you find something outdated, a missing citation, or confusing language, email the editorial team and we log the correction publicly. For a category where the rules change on a month-to-month basis and people are making real medical decisions, we think this is the floor, not the ceiling.
The 2026 Catalyst Calendar
The report includes a dated catalyst calendar. These are the readouts, filings, and decisions most likely to move the obesity, GLP-1, and peptide market through the end of 2026.
April 10, 2026. Orforglipron FDA PDUFA date. If approved, it becomes the first once-daily oral GLP-1 without food or water restrictions.
First half 2026. Mazdutide DREAMS-3 readout, the first head-to-head phase 3 comparison of mazdutide against semaglutide.
June 7, 2026 (ADA Scientific Sessions). Eli Lilly quintuple agonist preclinical data, Poster 2839-LB.
Throughout 2026. Seven additional retatrutide phase 3 readouts across the TRIUMPH program.
Second half 2026. CagriSema FDA decision following the December 2025 NDA filing. Biohaven taldefgrobep alfa phase 2 obesity topline. NeuroBo DA-1726 phase 1 topline. Nimacimab 26-week extension data from Skye Bioscience.
Late 2026. Retatrutide FDA filing likely, with a decision window opening in 2027 and 2028.
Ongoing through 2026 and 2027. Pfizer PF-3944 VESPER-4 registrational phase 3 readouts. VK2735 VANQUISH phase 3 readouts. Survodutide SYNCHRONIZE and LIVERAGE phase 3 readouts. Ecnoglutide SLIMMER follow-on data. Pemvidutide phase 3 initiation.
Regulatory Catalysts on the Peptide Side
Late 2026. FDA publication of the consumer peptide explainer, which will set the tone for how peptide therapy is discussed in mainstream medicine for the rest of the decade.
Ongoing through 2026. Any reclassification of specific peptides on the 503A bulk substances list from Category 2 back to Category 1. Even one reclassification would be a significant market signal.
Ongoing through 2026. FTC posture on peptide marketing claims. A clear set of guidelines from the agency would change how the research peptide market communicates with patients.
Ongoing through 2026 and 2027. State-level legislation on peptide therapy, compounded GLP-1 access, and telemedicine oversight. Several states have introduced bills and more are expected.
Ongoing. International drug pricing pressure. If the Trump administration revives most-favored-nation pricing for GLP-1 drugs, the downstream effects on compounding and access will be significant.
Through 2028. Any federal legislation on peptide therapy or GLP-1 access will need to move before the 2028 election cycle consumes the legislative calendar.
Where the Report Is More Cautious
The report does not treat every candidate on the pipeline list as equally credible. Several signals are worth watching with skepticism.
NA-931 / Bioglutide data has drawn public credibility challenges from outside analysts. The report does not cite NA-931 as settled science and will revisit the compound only after independent verification.
Retatrutide has a dysesthesia signal at the 12 mg dose that appeared in 20.9 percent of participants. Whether this holds or softens in the larger phase 3 data set matters for the commercial trajectory.
CagriSema missed Novo Nordisk's internal 25 percent efficacy target. It will still likely be approved. It will not likely be the ceiling-setter many observers assumed it would be before the REDEFINE-1 readout.
MariTide is a GIP antagonist that produces weight loss. Tirzepatide is a GIP agonist that produces weight loss. Both work. The field's understanding of GIP biology is incomplete, and the report treats this as a signal that the science is still moving faster than the therapeutic narrative.
Monlunabant showed elevated withdrawal rates at higher doses. The CB1 psychiatric shadow from the rimonabant era has not fully lifted.
Taldefgrobep alfa missed its primary endpoint in spinal muscular atrophy. The obesity pivot is a rescue play. The body composition signals are real, but the program is not yet on the same footing as bimagrumab.
Updated analysis on each of these is published monthly on the FormBlends research hub at formblends.com/research.
About FormBlends
FormBlends is a telehealth platform. We do two things: medically supervised GLP-1 therapy for patients who qualify, and a free research reference for anyone tracking peptides, GLP-1s, metabolic health, and longevity medicine. We sell compounded semaglutide and compounded tirzepatide only, and only after a full medical assessment. Everything else on the site is educational.
The research hub pulls together FDA guidance, ClinicalTrials.gov data, peer-reviewed papers, and jurisdictional summaries into one searchable reference. It's free to use. We update it continuously, with named editorial writers and a licensed clinician review on every page.
FormBlends is based in Miami. We serve patients in states where our licensed clinical partners are authorized to practice. The clinician network includes physicians and nurse practitioners credentialed in obesity medicine, endocrinology, and primary care. Compounding is handled by independently licensed 503A and 503B pharmacies that meet our internal quality standards.
For more, to start a medical assessment, or to dig into the research library, visit formblends.com.
Media Contact
FormBlends Press Office press@formblends.com https://formblends.com
Compliance and Safety Notices
FormBlends is a telehealth platform that connects patients with independent licensed clinicians and licensed pharmacies. FormBlends does not manufacture medications and does not practice medicine.
Compounded medications are not FDA-approved and are not reviewed by the FDA for safety or efficacy. Compounding is permitted under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. Compounded medications are prepared for patients based on a prescription from a licensed clinician.
Weight loss and clinical outcomes vary. Results depend on individual factors including medical history, adherence, lifestyle, and clinician guidance. Individual results are not guaranteed.
Product names including Wegovy, Ozempic, Mounjaro, and Zepbound are the property of their respective manufacturers. References in this release are for factual and comparative context only and do not imply any affiliation, endorsement, or equivalency between FormBlends compounded medications and any branded product.
Information in this release about peptides not offered by FormBlends is provided for educational purposes. It does not constitute an offer to sell, a recommendation to use, or medical advice. Readers should consult a licensed clinician before making any medical decisions.
###